Top 10 Stocks to Buy for the Year 2016-17

Top 10 Stocks to Buy for the Year 2016-17

Stock market has seen a lot of change in the last two years. 2014 was a bullish year, where in 2015 the market was bearish. 2016 has been promising so far and after the budget things have gone in the investors favor. Making money from stock market can be easy if you do it rightly. Let us have a look on what are the best stocks to buy in 2016-17:

investment choices


Almost all the major stocks from the banking sector saw a 200 percent growth in 2014, whereas in 2015 it was the just the opposite. The banking stocks have gone down drastically in the last one year. The decrease in the share price of some valuable companies like SBI, Bank of Baroda have given you the entry point.

It is expected that if you buy these shares, you may make more than 25 percent in one year.

  1. SBI

A month ago, SBI had come down to 160. However, there has been a rally seen after the budget was announced. I am keeping my hopes high on SBI. SBI is a very good addition to your portfolio.

You certainly can’t miss this chance of buying SBI shares now. Stick with the company and you may get more than 50 percent return in one year time.

  1. Axis Bank

Axis bank is another stock that you can buy if the price goes down below 400 INR, preferably below 385 INR. Sell it at 415-420 INR price range. Repeat atleast twice a month.

Banking Stocks to Avoid Currently

1. Federal bank

2. ICICI Bank

IT ( Information Technology )

The IT Sector has not performed as per the expectation. This sector is volatile and nothing can be predicted. However, I would still like to place my bet on the following two stocks:

  1. Tech Mahindra

Tech Mahindra has come down from 720 to 400 in one year. The current price of one share is 460 INR. You can either buy the share now or wait till the price goes down below 435 INR.

Selling Price: 550 INR- 570 INR. Tech Mahindra can give a very good return in the next one year. Hold the shares if you have bought them at a higher price.

        2. Infosys

Infosys looks very promising to me. The Infosys share value keeps fluctuating, but I don’t expect it to go below 1050. The price range stays in between 1050 and 1190. Infosys is a buy call below 1120 and sell call above 1180. Repeat the same atleast 5 times a month. You can earn 300 INR for every 1120 INR invested in one month.

Not bad, isn’t it?


Pharma sector has been ruling from the last few years and it is expected to rule in the coming years. Medicine making companies are making are making their money double or triple in 1-2 years. I am expecting a few pharma stocks to give a very good return by March 31, 2017. They are:

  1. CIPLA

Recently, the cost per share has gone down to 520 from 700 three months back. However, I am still optimistic about CIPLA. I am expecting CIPLA to touch 600 again in the next few months.

You may buy now at the current share price and may sell it when the price goes around 600.

  1. Aurobindo Pharma

Aurobindo Pharma, a stock from Pharma industry that went down from 850 to below 650. However from the last few days, the price has been increasing. The current price of one share of Aurobindo share is 717 INR. Buy it at 699 INR and sell the share at 750 INR.

More Pharma Shares where you may want to invest

  1. Sun Pharma: Buying price: Below 825 INR. Selling Price: 870 INR
  2. Torrent Pharma
  3. SMS Pharma

Miscellaneous shares Recommendation

  1. Buy SAIL at 35-36 price range and sell it around 40. Repeat the same. You will feel good.
  2. Buy ONGC
  3. Buy SAIL
  4. Buy BHEL

Shares from Other Sectors

  1. Apollo Hospital- This is one of the best share from healthcare industry. Buy at 1420 INR or below and Sell it at 1450 INR.
  2. Narayana Hrudalaya- Undoubtedly, Narayana Hrudalaya is again one of the best shares to buy from healthcare industry. The current price is 300 INR.

If you are looking for investment tips, feel free to visit our website again. If you have any input which you would like to share with us, feel free to do so under comments.

Image Credit: Forbes

Share This Post